Sana Biotechnology (NASDAQ:SANA) Upgraded to “Buy” at TD Cowen

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a buy rating in a report issued on Wednesday morning, MarketBeat.com reports.

Other research analysts have also issued reports about the company. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research note on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $4.30 on Wednesday. The firm’s 50-day moving average is $2.39 and its 200-day moving average is $4.07. The company has a market cap of $960.06 million, a price-to-earnings ratio of -3.07 and a beta of 1.45. Sana Biotechnology has a 52-week low of $1.52 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. Equities analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Trading of Sana Biotechnology

Several institutional investors have recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB bought a new position in shares of Sana Biotechnology during the third quarter valued at $29,000. Barclays PLC increased its position in shares of Sana Biotechnology by 126.6% during the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after purchasing an additional 178,179 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock valued at $13,175,000 after purchasing an additional 276,055 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Sana Biotechnology in the third quarter valued at about $45,000. Finally, State Street Corp grew its stake in Sana Biotechnology by 4.2% during the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after buying an additional 269,274 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.